Get the Stockscreener App
4.72
2.48%
-0.12
Cellectar Biosciences Inc stock is traded at $4.72, with a volume of 84,512.
It is down -2.48% in the last 24 hours and down -2.88% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$4.84
Open:
$4.921
24h Volume:
84,512
Relative Volume:
0.01
Market Cap:
$8.55M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-1.4523
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
-7.27%
1M Performance:
-2.88%
6M Performance:
+1,777%
1Y Performance:
+129.13%
1-Day Range:
$4.4406
$4.921
1-Week Range:
$4.4406
$5.38
52-Week Range:
$0.224
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
4.72 | 13.83M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Should I hold or sell Cellectar Biosciences Inc. stock in 2025Breakout Stocks Picks For Every Investor - jammulinksnews.com
Is it the right time to buy Cellectar Biosciences Inc. stockPost Market Picks With Low Risk - jammulinksnews.com
Why Cellectar Biosciences Inc. stock attracts strong analyst attentionStable Growth Stock Overview Signal - beatles.ru
What’s the recovery path for long term holders of Cellectar Biosciences Inc.Market Momentum and Signal Alerts Suggest Reversal - metal.it
Cellectar Biosciences Inc.’s Price Action Aligns with Quant SignalsFree Stock Market Practical Discussion Forums - beatles.ru
How to recover losses in Cellectar Biosciences Inc. stockLow Risk Stock Selection Strategy Guide - Newser
How to manage a losing position in Cellectar Biosciences Inc.Day Trading Setup Forecast with Trend Model - Newser
Cellectar Biosciences Inc. Could See a Relief Rally From SupportExit Ready Momentum Stock Watchlist Expanded - metal.it
Screener Results Flag Cellectar Biosciences Inc. as OversoldConsistent Gain Investment Strategies Emerge - metal.it
Published on: 2025-07-29 16:45:28 - metal.it
How high can Cellectar Biosciences Inc. stock goWeekly Setup Summary for Risk Controlled Trades - Newser
Why did Cellectar's operating expenses surge in Q4 2024? - AInvest
Published on: 2025-07-29 04:25:46 - Newser
Technical analysis overview for Cellectar Biosciences Inc. stockSwing Candidate List with Trade Cues - Newser
Why is Cellectar Biosciences Inc. stock attracting strong analyst attentionExpert Picks Outlook To Watch Now - jammulinksnews.com
What makes Cellectar Biosciences Inc. stock price move sharplyMarket-beating performance - jammulinksnews.com
How to manage a losing position in Cellectar Biosciences Inc. Predictive Screener for Daily Trade Watch - Newser
Is Cellectar Biosciences Inc. stock overvalued or undervaluedAI Powered Review For 2025 - jammulinksnews.com
What are analysts’ price targets for Cellectar Biosciences Inc. in the next 12 monthsMaximize your portfolio’s growth potential - jammulinksnews.com
Is Cellectar Biosciences Inc. a growth stock or a value stockAchieve breakthrough gains with expert advice - jammulinksnews.com
What is Cellectar Biosciences Inc. company’s growth strategyBuild your wealth with consistent stock growth - jammulinksnews.com
How does Cellectar Biosciences Inc. generate profit in a changing economyRapid-fire capital growth - jammulinksnews.com
Published on: 2025-07-27 20:39:48 - jammulinksnews.com
Intrinsic Value of Cellectar Biosciences Inc. Stock: Is It Undervalued or OvervaluedFree Professional Portfolio Management - Newser
What are the latest earnings results for Cellectar Biosciences Inc.Get real-time alerts on top-performing stocks - jammulinksnews.com
How Cellectar Biosciences Inc. stock performs during market volatilitySmart Trading With Safety Margin - Newser
Cellectar Biosciences Inc. Stock Analysis and ForecastPhenomenal capital gains - PrintWeekIndia
What institutions are buying Cellectar Biosciences Inc. stock nowExplosive wealth accumulation - jammulinksnews.com
Is Cellectar Biosciences Inc. a good long term investmentConsistent triple returns - PrintWeekIndia
What drives Cellectar Biosciences Inc. stock priceMassive wealth growth - Autocar Professional
What analysts say about Cellectar Biosciences Inc. stockExceptional trading performance - Autocar Professional
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cellectar Biosciences Inc Stock (CLRB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
| Longcor Jarrod | Chief Operating Officer |
Jan 10 '25 |
Buy |
0.28 |
30,000 |
8,400 |
83,141 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):